 Jazz Pharmaceuticals said on Wednesday it would buy GW Pharmaceuticals in a 7.2 billion cash-and-stock deal to bolster its neuroscience business by adding cannabis-based epilepsy treatment. CNBCs Jim Cramer and David Faber discuss. 